SpectraCure AB (OSTO:SPEC) EBIT: kr-54.68 Mil (TTM As of Mar. 2026)


What is SpectraCure AB EBIT?

SpectraCure AB OSTO:SPEC +2.03% EBIT is kr-54.68 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

SpectraCure AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-6.07 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-54.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SpectraCure AB's annualized ROC % for the quarter that ended in Mar. 2026 was -24.48%. SpectraCure AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -869.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SpectraCure AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -480.32%.

SpectraCure AB  (OSTO:SPEC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SpectraCure AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-24.288 * ( 1 - 0% )/( (97.209 + 101.244)/ 2 )
=-24.288/99.2265
=-24.48 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=104.468 - 1.709 - ( 13.525 - max(0, 10.674 - 16.224+13.525))
=97.209

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=111.01 - 1.552 - ( 16.594 - max(0, 10.596 - 18.81+16.594))
=101.244

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

SpectraCure AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.28/( ( (3.049 + max(-7.014, 0)) + (2.538 + max(-7.306, 0)) )/ 2 )
=-24.28/( ( 3.049 + 2.538 )/ 2 )
=-24.28/2.7935
=-869.16 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.598 + 0 + 0.491) - (1.709 + 0 + 6.394)
=-7.014

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.656 + 0 + 0.447) - (1.552 + 0 + 6.857)
=-7.306

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SpectraCure AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-54.68/11.384
=-480.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpectraCure AB EBIT Related Terms

SpectraCure AB EBIT Historical Data

* Premium members only.

The historical data trend for SpectraCure AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpectraCure AB EBIT Chart

SpectraCure AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.10 -25.20 -19.94 -22.54 -54.80

SpectraCure AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.19 -6.49 -34.62 -7.49 -6.07

OSTO:SPEC vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, SpectraCure AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpectraCure AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraCure AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SpectraCure AB's EV-to-EBIT falls into.


SpectraCure AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-54.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-54.68 Mil mean?
SpectraCure AB (OSTO:SPEC) has a EBIT of kr-54.68 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SpectraCure AB.
Is SpectraCure AB's EBIT too high?
SpectraCure AB's current EBIT is kr-54.68 Mil.
How does SpectraCure AB's EBIT compare to ABT and SYK?
SpectraCure AB's EBIT of kr-54.68 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SpectraCure AB. SpectraCure AB's current EBIT is kr-54.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpectraCure AB stock overvalued right now?
SpectraCure AB (OSTO:SPEC) has a current EBIT of kr-54.68 Mil. The current EBIT is kr-54.68 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For SpectraCure AB (OSTO:SPEC), the current EBIT is kr-54.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpectraCure AB Business Description

Address Magistratsvagen 10, Lund, SWE, 22643
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.